Shares of Bristol-Myers Squibb Company (NYSE:BMY) have been given a consensus rating of “Hold” by the twenty-five research firms that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $62.00.

Several brokerages have weighed in on BMY. Vetr upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.08 target price on the stock in a research report on Thursday. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday. BidaskClub lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Leerink Swann decreased their target price on shares of Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating on the stock in a research report on Friday, July 28th. Finally, Piper Jaffray Companies set a $60.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Thursday, July 27th.

In other news, Director Theodore R. Samuels II bought 6,000 shares of the stock in a transaction dated Wednesday, August 2nd. The shares were acquired at an average price of $55.94 per share, with a total value of $335,640.00. Following the acquisition, the director now owns 18,000 shares in the company, valued at $1,006,920. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.23% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. American National Bank increased its position in Bristol-Myers Squibb by 36.0% in the first quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 508 shares during the last quarter. Tradewinds Capital Management LLC increased its stake in shares of Bristol-Myers Squibb by 34.6% in the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 500 shares during the period. Welch Investments LLC increased its stake in shares of Bristol-Myers Squibb by 3.9% in the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 79 shares during the period. Crestwood Advisors Group LLC bought a new stake in shares of Bristol-Myers Squibb during the first quarter valued at approximately $116,000. Finally, Blue Chip Partners Inc. increased its stake in shares of Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 17 shares during the period. Institutional investors own 69.79% of the company’s stock.

WARNING: This article was published by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.dailypolitical.com/2017/08/11/bristol-myers-squibb-company-bmy-receives-consensus-recommendation-of-hold-from-analysts.html.

Bristol-Myers Squibb (NYSE:BMY) traded up 0.25% during trading on Friday, hitting $56.73. The company’s stock had a trading volume of 4,060,330 shares. The firm has a market cap of $93.03 billion, a PE ratio of 20.72 and a beta of 1.17. The company has a 50-day moving average of $55.82 and a 200 day moving average of $54.60. Bristol-Myers Squibb has a one year low of $46.01 and a one year high of $61.30.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.01. The firm had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.69 earnings per share. On average, equities analysts forecast that Bristol-Myers Squibb will post $2.97 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, August 1st. Shareholders of record on Friday, July 7th were issued a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 2.75%. The ex-dividend date of this dividend was Wednesday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 56.73%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Analyst Recommendations for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.